ACT-1014-6470
ACT-1014-6470 is an orally active, potent, reversible, and selective C5aR1 antagonist. ACT-1014-6470 demonstrates potent inhibition of C5aR1 activation. ACT-1014-6470 can be used in the research of inflammatory diseases[1][2].
Product Specifications
CAS Number
[2363082-87-3]
UNSPSC
12352005
Target
Complement System
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
O=C1N(CC2=CC=CC=C2C(F)(F)F)C3=NN(CC(F)(F)C)C=C3CN1C4CCN(C5=C(C)C=CC=C5F)CC4
Molecular Formula
C28H29F6N5O
Molecular Weight
565.55
References & Citations
[1]Sylvie FROIDEVAUX, et al. 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseases. WO2019137927A1. WIPO (PCT) . 2019-01-09. |[2]Ort M, et al. First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients. Basic Clin Pharmacol Toxicol. 2022 Aug;131 (2) :114-128.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1136131-01 0.5 mg (E-Coli)
Recombinant Streptococcus pneumoniae UPF0154 protein SPH_1998 (SPH_1998), partial
Ask
View Details MBS1136131-02 0.05 mg (Baculovirus)
Recombinant Streptococcus pneumoniae UPF0154 protein SPH_1998 (SPH_1998), partial
Ask
View Details MBS1136131-03 0.5 mg (Yeast)
Recombinant Streptococcus pneumoniae UPF0154 protein SPH_1998 (SPH_1998), partial
Ask
View Details MBS1136131-04 0.05 mg (Mammalian-Cell)
Recombinant Streptococcus pneumoniae UPF0154 protein SPH_1998 (SPH_1998), partial
Ask
View Details